<DOC>
	<DOCNO>NCT00200499</DOCNO>
	<brief_summary>The study conduct determine long-term safety efficacy nebivolol patient mild moderate hypertension . This extension Phase III dose range study NEB 202 , 302 305 . Nebivolol study monotherapy conjunction add-on antihypertensive therapy .</brief_summary>
	<brief_title>A Study Safety Efficacy Long-Term Nebivolol Use Hypertensive Patients</brief_title>
	<detailed_description>This international , multicenter parallel group , 9-month extension study 4-week follow-up phase evaluate long-term safety efficacy nebivolol administer orally daily patient mild moderate hypertension ( defined average sit diastolic blood pressure great equal 95 mmHg less equal 109 mmHg untreated , base entry NEB 202 , NEB 302 NEB 305 ) . Patients permit protocol-defined concomitant use diuretic calcium antagonist . After successful completion one 3-month efficacy `` feeder '' study , patient eligible continue nebivolol treatment 9-month extension study . Patients complete extension phase receive nebivolol monotherapy extension phase eligible enter 1-month follow-up phase .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>To enter longterm treatment phase , patient must successfully complete NEB 202 , NEB 302 , NEB 305 . To enter 4week followup phase , patient must complete NEB306 ( extension phase ) receive nebivolol monotherapy treatment NEB 306 . Secondary hypertension myocardial infarction stroke contraindication betablocker therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Beta-Blocker</keyword>
</DOC>